Helen Sabzevari Sells 346,836 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 346,836 shares of Precigen stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.89, for a total value of $2,042,864.04. Following the completion of the transaction, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Sabzevari also recently made the following trade(s):

• On Thursday, May 28th, Helen Sabzevari sold 119,250 shares of Precigen stock. The stock was sold at an average price of $4.36, for a total value of $519,930.00.

Precigen Price Performance

Shares of PGEN stock opened at $5.64 on Friday. Precigen, Inc. has a 52 week low of $1.47 and a 52 week high of $6.04. The stock has a market capitalization of $2.01 billion, a PE ratio of -4.78 and a beta of 1.00. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The stock’s fifty day moving average is $4.46 and its 200-day moving average is $4.24.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $23.25 million during the quarter, compared to analysts’ expectations of $20.81 million. Equities research analysts expect that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Boxer Capital Management LLC bought a new stake in shares of Precigen during the third quarter worth approximately $2,796,000. Occam Crest Management LP boosted its stake in Precigen by 29.6% in the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after acquiring an additional 799,339 shares during the last quarter. Investment Insight Wealth Management LLC acquired a new stake in Precigen during the 4th quarter worth $443,000. UBS Group AG raised its position in shares of Precigen by 41.4% during the 4th quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock valued at $3,726,000 after acquiring an additional 260,824 shares during the last quarter. Finally, Impala Asset Management LLC acquired a new position in shares of Precigen in the 4th quarter valued at $690,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Citizens Jmp upped their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Finally, Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.